Company
Boston
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
0
Approvals since 2021
0
Originals and new uses
Phase 3 trials
52
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Varithena approved Nov 25, 2013
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin CancerPivotal-lookingRecruiting
Boston UniversityAcademic, hospital or other
NCT05381597 · 200 participants (planned) · Start Oct 15, 2022 · Primary completion Jun 2027
Drug: Combination cream of 5-fluorouracil and calcipotriene; 5-fluorouracil cream · For: Superficial Basal Cell Carcinoma; Squamous Cell Carcinoma in Situ
Sites: Boston, Massachusetts
- Effectiveness and Safety of TENS Therapy for Premature EjaculationPivotal-lookingRecruiting
Boston Medical GroupIndustry
NCT06425224 · 129 participants (planned) · Start Jun 15, 2022 · Primary completion Jun 2025
Drug: Dapoxetine placebo; Standard treatment (dapoxetine 30 mg as needed) · For: Premature Ejaculation; Sex Disorder; TEN
Sites: Mexico City, Mexico
Marketed drugs (1)
Newest FDA action first.
- Varithena Polidocanol · 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.